Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
6 hedge funds and large institutions have $10.6M invested in Celyad Oncology SA American Depositary Shares in 2016 Q2 according to their latest regulatory filings, with funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
25% less funds holding
Funds holding: 8 → 6 (-2)
47% less capital invested
Capital invested by funds: $19.8M → $10.6M (-$9.27M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
+$163K |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$43.8K |
| 3 |
Morgan Stanley
New York
|
+$1.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.32M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$135K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$35.9K |
| 4 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$966 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RIM
1
RS Investment Management
San Francisco,
California
| $8.18M | -$135K | -2,843 | -0.9% |
|
|
CAM
2
Cormorant Asset Management
Boston,
Massachusetts
| $1.9M | +$43.8K | +920 | +1% |
|
|
3
Zurich Cantonal Bank
Zurich,
Switzerland
| $429K | +$163K | +3,426 | +25% |
|
|
4
Morgan Stanley
New York
| $45K | +$1.81K | +38 | +2% |
|
|
5
UBS Group
Zurich,
Switzerland
| $13K | -$35.9K | -754 | -59% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $8K | – | – | – |
|
|
DCM
7
DAFNA Capital Management
Los Angeles,
California
| – | -$1.32M | -30,000 | Closed |
|
|
VIA
8
Vident Investment Advisory
Alpharetta,
Georgia
| – | -$966 | -21,872 | Closed |
|
CYAD Hedge Fund Activity: Q2 2016 in Review
6 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q2 2016, worth a combined $10.6M — down 47% from $19.8M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CYAD and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Zurich Cantonal Bank, adding an estimated $163K. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $1.32M sold.
- 6 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q2 2016, down from 8 in Q1 2016.
- Funds reported $10.6M of Celyad Oncology SA American Depositary Shares stock for Q2 2016, down 47% quarter-over-quarter.
- 0 funds opened new Celyad Oncology SA American Depositary Shares positions in Q2 2016 and 2 closed out, a net change of -2 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q2 2016 was Zurich Cantonal Bank, an estimated $163K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q2 2016 was DAFNA Capital Management, an estimated $1.32M sold.
Based on aggregated 13F filings for Q2 2016.